CannRx
Science-based Cannabis Technologies
Company Overview
Snapshot
Founded in January 2017 by William Z. Levine, CannRx operates with 1–10 employees. The company holds a patent and ceased operations in May 2022.
Business overview
CannRx develops proprietary science-based cannabis technologies, specializing in sleep and pain research, and creating products for oncology support, Parkinson's disease, women's health, and the sports industry. Its core products include ican.sleep, a formulation for sleep disorders, and Vapor Capture Technology (VCT), an extraction method for cannabis. The company also utilizes patented nanoparticle technology to enhance cannabinoid solubility. CannRx operates within the Health Tech & Life Sciences sector, specifically focusing on medical cannabis and pharmaceuticals, serving markets such as the United States and Europe.
Strategic signal
In March 2018, CannRx announced the commercial model of its Vapor Capture Technology (VCT), a revolutionary extraction technology designed specifically for the cannabis plant. This development signaled the company's move towards commercializing its proprietary extraction methods, offering a pre-activated, highly bio-available cannabis extract with a unique cannabinoid/terpene profile. For investors, this highlighted CannRx's potential to disrupt the cannabis extraction market with advanced, science-backed solutions.
Log in to access full profile ›Company Intelligence Q&A
- What is CannRx's primary focus?
- CannRx focuses on developing proprietary science-based cannabis technologies, with a specialization in sleep and pain research, and creating products for oncology support, Parkinson's disease, women's health, and the sports industry.
- When was CannRx founded and by whom?
- CannRx was founded in January 2017 by William Z. Levine.
- What is CannRx's Vapor Capture Technology (VCT)?
- Vapor Capture Technology (VCT) is an extraction technology developed by CannRx specifically for the cannabis plant, which provides a pre-activated, highly bio-available cannabis extract with a unique cannabinoid/terpene profile. The commercial model for VCT was announced in March 2018.
- What is ican.sleep?
- ican.sleep is a proprietary formulation developed by CannRx that targets sleep disorders. In March 2017, CannRx and iCAN:Israel-Cannabis announced a joint venture to market this advanced sleep cannabis formulation.
- What is the status of CannRx?
- CannRx ceased to operate in May 2022.